Discovery

LIVE May 20th, 2021 at 2:30 PM ET
In this webinar, Berkeley Lights scientists present a new platform for antibody discovery and cell line development that accelerates the identification and production of leading therapeutic molecules.

Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials.

Findings showed that Previse could predict the onset of AKI up to 48 hours in advance of onset, sooner than the standard hospital systems like XGBoost AKI prediction model and the Sequential Organ Failure Assessment (SOFA).

With a focus on comprehensive molecular disease classification, combined with prospective clinical outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations,” he added.

A look at some of the latest renal and hepatic R&D

Therapeutic candidates retain binding to major COVID-19-causing “South African” variant

ConserV Bioscience and eTheRNA immunotherapies collaborate on mRNA vaccines for infectious diseases

Genomenon and BC Platforms seek to combine their tech platforms to boost genomic research

Grant from Innovate UK to Pathios seeks to advance cancer immunotherapy

Weill Neurohub joins forces with Genentech and Roche on neuroscience and CNS disorders